Michael A. Carrier and Steve D. Shadowen published the article “Don’t Ditch Antitrust’s Role in Product Hopping: A Response to Pace and Adam” in Antitrust Magazine (Spring 2019, Vol. 33, No. 2).
When a brand drug firm reformulates its product, encourages doctors to prescribe the new version, and can offer no justification other than harming generic rivals, antitrust liability should be on the table. We thus disagree with Jack E. Pace III and Kevin C. Adam, who would limit antitrust liability to deceptive reformulations or sham innovation. This short piece discusses.
Carrier and Shadowen also teamed up on product hopping for a Notre Dame Law Review article “Product Hopping: A New Framework” in Volume 92, Issue 1 in 2017.